{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:04:37Z","timestamp":1788822277662,"version":"build-2803163510"},"reference-count":71,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH-HFpEF) represents a frequent form of PH related to left ventricular dysfunction. The pathophysiology of PH-HFpEF is intricate, and varied and includes vascular, cardiac, and pulmonary factors that contribute synergistically to developing this clinical syndrome. Improved knowledge of the pathophysiology of PH-HFpEF has paved the way for the use of new drugs such as angiotensin receptor neprilysin inhibitors (ARNIs), non-steroidal mineral corticoid receptor antagonist (nsMRA), sodium-glucose cotransporter inhibitors (SGLT2is), levosimendan, and glucagon-like peptide 1 (GLP-1) agonists. ARNIs are a widely used drug for the treatment of PH associated with heart failure with reduced ejection fraction. They have also recently been used in PH-HFpEF patients with hemodynamic benefits that need to be confirmed in future research. Finerenone is an innovative non-steroidal mineralocorticoid receptor antagonist that exhibits notable cardioprotective and renoprotective properties in individuals suffering from chronic diabetic kidney disease. It also enhances outcomes for patients with heart failure, whether they have mildly reduced or preserved ejection fraction. Moreover, in experimental studies, finerenone has been found to lower pulmonary artery pressure, reduce muscularization, and decrease the wall thickness of pulmonary arteries. SGLT2i have revolutionized the treatment of patients with heart failure irrespective of left ventricular ejection fraction, and their treatment is also associated with an improvement in the hemodynamics profile in patients with PH-HFpEF. Levosimendan is a widely used inodilator in the treatment of acute and advanced heart failure. In addition, its use in patients with PH-HFpEF (supported by the positive effects on pulmonary hemodynamics that levosimendan exerts) has recently demonstrated hemodynamic benefit in a small phase 2 study that paved the way for phase 3 studies and the creation of an oral formulation of levosimendan. Finally, GLP1 agonists are a class of drugs that, in preliminary evidence, have shown a positive effect on cardiac hemodynamics, mainly by facilitating left ventricular unloading. These effects, along with the reduction in insulin resistance and weight loss, likely lead to beneficial outcomes for PH-HFpEF patients, especially those with obesity as a comorbidity.<\/jats:p>","DOI":"10.3390\/jcm13226867","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T09:14:31Z","timestamp":1731575671000},"page":"6867","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-7424","authenticated-orcid":false,"given":"Daniele","family":"Masarone","sequence":"first","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Valente","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Verrengia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Contaldi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"di Palma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5669-574X","authenticated-orcid":false,"given":"Luigi","family":"Falco","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Catapano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"di Lorenzo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1164\/rccm.201503-0529OC","article-title":"Pulmonary Hypertension in Heart Failure. Epidemiology, Right Ventricular Function, and Survival","volume":"192","author":"Gerges","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction","volume":"138","author":"Carter","year":"2018","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.cjca.2020.11.003","article-title":"Pulmonary Hypertension Due to Left Heart Disease-A Practical Approach to Diagnosis and Management","volume":"37","author":"Lee","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.21037\/cdt-19-405","article-title":"Pulmonary arterial hypertension and heart failure with preserved ejection fraction: Are they so discordant?","volume":"10","author":"Ruocco","year":"2020","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.chest.2021.08.039","article-title":"Pulmonary Hypertension in the Context of Heart Failure with Preserved Ejection Fraction","volume":"160","author":"Inampudi","year":"2021","journal-title":"Chest"},{"key":"ref_10","first-page":"2869","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: A plea for proper phenotyping and further research","volume":"38","author":"Hoeper","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIRCHEARTFAILURE.113.000887","article-title":"Cardiac structure and function in heart failure with preserved ejection fraction: Baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic Features of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.cpcardiol.2024.102537","article-title":"Prevalence and impact of pulmonary hypertension on acute decompensated heart failure with preserved ejection fraction hospitalizations: A five-year retrospective analysis","volume":"49","author":"Wahadneh","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.amjcard.2006.11.052","article-title":"Prognostic importance of pulmonary hypertension in patients with heart failure","volume":"99","author":"Kjaergaard","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"H1498","DOI":"10.1152\/ajpheart.00068.2024","article-title":"Novel insights into the pathobiology of pulmonary hypertension in heart failure with preserved ejection fraction","volume":"326","author":"Aradhyula","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.21037\/cdt-20-477","article-title":"Left ventricular dysfunction in heart failure with preserved ejection fraction-molecular mechanisms and impact on right ventricular function","volume":"10","author":"Heinzel","year":"2020","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pcad.2016.05.002","article-title":"Lung Capillary Stress Failure and Arteriolar Remodelling in Pulmonary Hypertension Associated with Left Heart Disease (Group 2 PH)","volume":"59","author":"Dayeh","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1210\/jc.2011-1182","article-title":"Cardiac natriuretic peptides, obesity, and insulin resistance: Evidence from two community-based studies","volume":"96","author":"Khan","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41598-018-19619-0","article-title":"Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes","volume":"8","author":"Barquissau","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.biopha.2017.07.027","article-title":"A natriuretic peptides clearance receptor\u2019s agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: New hope for patients with pulmonary hypertension due to left ventricular heart failure","volume":"93","author":"Egom","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_23","first-page":"112","article-title":"New insights and new hope for pulmonary arterial hypertension: Natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease","volume":"9","author":"Egom","year":"2017","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sarzani, R., Allevi, M., Di Pentima, C., Schiavi, P., Spannella, F., and Giulietti, F. (2022). Role of Cardiac Natriuretic Peptides in Heart Structure and Function. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214415"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13036-017-0093-0","article-title":"Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure","volume":"12","author":"Fu","year":"2018","journal-title":"J. Biol. Eng."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rubattu, S., and Volpe, M. (2019). Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20163991"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCHEARTFAILURE.110.958801","article-title":"Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction","volume":"4","author":"Thenappan","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pcad.2016.06.002","article-title":"Development of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction","volume":"59","author":"Farr","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bruck, O., and Pandit, L.M. (2024). Pulmonary Hypertension and Hyperglycemia-Not a Sweet Combination. Diagnostics, 14.","DOI":"10.3390\/diagnostics14111119"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.2337\/db06-0885","article-title":"The leptin-deficient (ob\/ob) mouse: A new animal model of peripheral neuropathy of type 2 diabetes and obesity","volume":"55","author":"Drel","year":"2006","journal-title":"Diabetes"},{"key":"ref_31","first-page":"1935","article-title":"Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice","volume":"7","author":"Aytekin","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1165\/rcmb.2016-0177OC","article-title":"Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction","volume":"56","author":"Meng","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zanotto, T.M., Gon\u00e7alves, A.E.S.S., and Saad, M.J.A. (2024). Pulmonary hypertension and insulin resistance: A mechanistic overview. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1283233"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"H1556","DOI":"10.1152\/ajpheart.00076.2015","article-title":"Echocardiography and invasive hemodynamics during stress testing for diagnosis of heart failure with preserved ejection fraction: An experimental study","volume":"308","author":"Leite","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","article-title":"Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model","volume":"6","author":"Hamdani","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"170094","DOI":"10.1183\/16000617.0094-2017","article-title":"Metabolic dysfunction in pulmonary hypertension: From basic science to clinical practice","volume":"26","author":"Chan","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCRESAHA.118.314555","article-title":"Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease","volume":"125","author":"Ranchoux","year":"2019","journal-title":"Circ. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102542","DOI":"10.1016\/j.arr.2024.102542","article-title":"The Aging Heart in Focus: The Advanced Understanding of Heart Failure with Preserved Ejection Fraction","volume":"101","author":"Zhang","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e024449","DOI":"10.1161\/JAHA.121.024449","article-title":"Effect of Sacubitril\/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies","volume":"11","author":"Zhang","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e006696","DOI":"10.1161\/CIRCHEARTFAILURE.119.006696","article-title":"Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation","volume":"13","author":"Zern","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Burgdorf, C., Brockm\u00f6ller, J., Strampe, H., Januszewski, M., and Remppis, B.A. (2021). Reduction of Pulmonary Hypertension After Transition to Sacubitril\/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.734697"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/ehf2.13952","article-title":"Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension","volume":"9","author":"Codina","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Xu, Y., Yang, B., Hui, J., Zhang, C., Bian, X., Tao, M., Lu, Y., Wang, W., Qian, H., and Shang, Z. (2023). The emerging role of sacubitril\/valsartan in pulmonary hypertension with heart failure. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1125014"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared with Men with Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhai, S., Ma, B., Chen, W., and Zhao, Q. (2024). A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1476029"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","article-title":"Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats","volume":"79","author":"Tu","year":"2022","journal-title":"Hypertension"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights into the Heart Failure Benefits of SGLT2 Inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"107631","DOI":"10.1016\/j.rmed.2024.107631","article-title":"Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension","volume":"227","author":"Luo","year":"2024","journal-title":"Respir. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e12028","DOI":"10.1002\/pul2.12028","article-title":"Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension","volume":"12","author":"King","year":"2022","journal-title":"Pulm. Circ."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","article-title":"SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery","volume":"309","author":"Han","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","volume":"524","author":"Chowdhury","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients\u2014A Randomized Controlled Trial","volume":"84","author":"Kayano","year":"2020","journal-title":"Circ. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results From the EMBRACE-HF Trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure with Preserved Ejection Fraction: The CAMEO-DAPA Trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Masarone, D., Kittleson, M.M., Pollesello, P., Marini, M., Iacoviello, M., Oliva, F., Caiazzo, A., Petraio, A., and Pacileo, G. (2022). Use of Levosimendan in Patients with Advanced Heart Failure: An Update. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216408"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40265-022-01833-w","article-title":"Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?","volume":"83","author":"Masarone","year":"2023","journal-title":"Drugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e175634","DOI":"10.1172\/JCI175634","article-title":"The GLP-1 journey: From discovery science to therapeutic impact","volume":"134","author":"Drucker","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","article-title":"Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial","volume":"9","author":"Burkhoff","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1002\/ehf2.13669","article-title":"Levosimendan-induced venodilation is mediated by opening of potassium channels","volume":"8","author":"Burkhoff","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rowlands, J., Heng, J., Newsholme, P., and Carlessi, R. (2018). Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00672"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Le, R., Nguyen, M.T., Allahwala, M.A., Psaltis, J.P., Marathe, C.S., Marathe, J.A., and Psaltis, P.J. (2024). Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs. J. Clin. Med., 13.","DOI":"10.3390\/jcm13164674"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1002\/edm2.462","article-title":"Glucagon-like peptide agonists: A prospective review","volume":"7","author":"Mariam","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1038\/s41598-020-74912-1","article-title":"GLP-1 receptor agonist ameliorates experimental lung fibrosis","volume":"10","author":"Toba","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e37432","DOI":"10.1097\/MD.0000000000037432","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"103","author":"Xia","year":"2024","journal-title":"Medicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial","volume":"18","author":"Bizino","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","article-title":"Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes","volume":"17","author":"Lambadiari","year":"2018","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6867\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:32:30Z","timestamp":1760113950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":71,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13226867"],"URL":"https:\/\/doi.org\/10.3390\/jcm13226867","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}